Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival. (Q53057385)

10 May 2018

editorial

0 references

title

Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival. (English)

1 reference

10 May 2018

author

Thomas Helleday

series ordinal

1

1 reference

10 May 2018

publication date

15 April 2014

1 reference

10 May 2018

published in

Annals of Oncology

1 reference

10 May 2018

volume

25

1 reference

10 May 2018

issue

7

1 reference

10 May 2018

page(s)

1253-1255

1 reference

10 May 2018

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Bortezomib as an antitumor agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU158

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU158

1 reference

10 May 2018

PubMed ID

24737777

1 reference

10 May 2018